In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis ...

Among patients with resected stage 3B to 4 melanoma, postsurgical treatment with Opdivo (nivolumab) was associated with a ...

In the intent-to-treat population, the median progression-free survival (PFS) was 8.77 months with giredestrant plus Afinitor ...

Results presented at the European Society for Medical Oncology meeting could help separate Roche’s medicine from similar ...

Introduction Therapeutic exercise has been used to improve cancer-related dysfunction. Recent studies suggest that exercise after chemotherapy can improve cancer-related cognitive impairment. However, ...

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono"), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of ...